Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CFRX

ContraFect (CFRX) Stock Price, News & Analysis

ContraFect logo

About ContraFect Stock (NASDAQ:CFRX)

Key Stats

Today's Range
$0.05
$0.06
50-Day Range
$0.05
$0.07
52-Week Range
$0.04
$13.02
Volume
910,200 shs
Average Volume
1.39 million shs
Market Capitalization
$535,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

CFRX Stock News Headlines

22R.BE,0P0001D9RF,0 (22R.BE)
RegenETP, Inc. (RGTPQ)
Election warning coming true…
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
ContraFect Corp CFRXQ
ContraFect Corp CFRX
ContraFect: Q3 Earnings Snapshot
See More Headlines

CFRX Stock Analysis - Frequently Asked Questions

ContraFect Co. (NASDAQ:CFRX) issued its earnings results on Monday, November, 15th. The biotechnology company reported ($10.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($22.64) by $12.24.

Shares of ContraFect reverse split on Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Meta Platforms (META), Tonix Pharmaceuticals (TNXP), Novavax (NVAX), VBI Vaccines (VBIV) and Cidara Therapeutics (CDTX).

Company Calendar

Last Earnings
11/15/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CFRX
Fax
N/A
Employees
23
Year Founded
N/A

Profitability

Net Income
$-65,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($19.92) per share

Miscellaneous

Free Float
10,639,000
Market Cap
$535,000.00
Optionable
Not Optionable
Beta
0.29

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CFRX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners